PET imaging reveals abnormal brain circuitry and dopamine loss in individuals with isolated REM sleep behavior disorder, years before the onset of neurodegenerative diseases like Parkinson’s.
Summary:
New research from The Feinstein Institutes for Medical Research has shown that brain imaging can detect abnormal metabolic network activity and dopamine loss in individuals with isolated rapid eye movement (REM) sleep behavior disorder (iRBD), a condition often preceding neurodegenerative diseases like Parkinson’s and Lewy body dementia. Using PET imaging, researchers tracked these changes over four years and found that high network activity in iRBD patients increased their risk of developing progressive neurodegenerative disorders. The findings highlight the potential for brain imaging to predict disease progression and aid in earlier intervention strategies.
Key Takeaways:
- Abnormal Brain Networks in iRBD: PET imaging revealed disrupted brain circuits and declining dopamine levels in individuals with iRBD, even before they exhibited motor symptoms of Parkinson’s or related disorders.
- Predicting Disease Progression: Patients with higher network activity were at greater risk of developing neurodegenerative diseases, and brain imaging combined with dopamine analysis may help predict the likelihood and timing of progression.
- Window for Early Intervention: Researchers say the study underscores the value of brain imaging in identifying at-risk individuals during the earliest stages of disease, potentially enabling earlier diagnosis and targeted therapies.
Brain imaging can detect subtle abnormalities in brain circuitry in people diagnosed with isolated rapid eye movement (REM) sleep behavior disorder (iRBD) years before they manifest symptoms of a degenerative brain disorder, reveals new research from The Feinstein Institutes for Medical Research.
While involuntary movements are normally inhibited during REM sleep, individuals with iRBD act out their dreams and come to medical attention. This condition is often a precursor to progressive neurodegenerative disorders, most notably, Parkinson’s disease and a related disorder known as Lewy body dementia.
In a study led by David Eidelberg, MD, head of the Center for Neurosciences at the Feinstein Institutes and Susan and Leonard Feinstein Professor of Neurology and Neuroscience, published in Nature Communications, investigators used positron emission tomography (PET) to track abnormal metabolic network activity and dopamine loss in the brains of people with iRBD but no other signs of brain disease.
Longitudinal imaging studies were conducted over four years, after which subjects were followed clinically for an additional six and a half years to see whether other neurological symptoms had appeared. The investigators found that abnormal brain networks associated with the motor manifestations of Parkinson’s disease were present at baseline in iRBD, progressing steadily over time, while dopamine, the essential neurotransmitter for movement, concurrently declined.
The study also found that iRBD patients with high network activity were at greater risk for the subsequent development of a progressive neurodegenerative syndrome.
Brain Imaging Provides a ‘Window Into the Earliest Stages‘ of Parkinson’s Development
“This study is a significant advancement in Parkinson’s disease research because it provides a window into the earliest stages of disease development, even before the onset of typical motor symptoms,” says Eidelberg in a release. “By identifying brain changes in individuals with iRBD, we can potentially determine who is at highest risk for the subsequent development of a progressive, disabling brain disorder. This may pave the way for earlier interventions and ultimately, more effective disease-modifying therapies.”
Scientists have been searching for ways to predict when iRBD might progress. This study found that the connections between critical brain regions changed over time in individuals with iRBD, disrupting the normal flow of information through motor and cognitive networks many years before Parkinson’s symptoms appeared. The results also suggest that the likelihood and timing of conversion from iRBD to Parkinson’s or Lewy body dementia may be accurately predicted using brain networks in conjunction with the dopamine imaging.
“This research holds immense promise for earlier diagnosis and treatment of Parkinson’s disease and dementia with Lewy bodies,” says Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research, in a release. “It suggests brain imaging is a valuable tool for tracking the effectiveness of new treatments designed to slow or prevent disease progression.”
ID 44030306 © Sudok1 | Dreamstime.com
